PROFILBARU.COM

Iproclozide
Clinical data
Routes of; administration	Oral
ATC code	N06AF06 (WHO) ;
Legal status
Legal status	BR: Class C1 (Other controlled substances); In general: uncontrolled;
Identifiers
	IUPAC name 2-(4-chlorophenoxy)-N-isopropyl-acetohydrazide;
CAS Number	3544-35-2 ;
PubChem CID	19063;
ChemSpider	17998 ;
UNII	1II9D6CB3J;
KEGG	D07338 ;
ChEMBL	ChEMBL91238 ;
CompTox Dashboard (EPA)	DTXSID70188925 ;
ECHA InfoCard	100.020.536
Chemical and physical data
Formula	C11H15ClN2O2
Molar mass	242.70 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1ccc(OCC(=O)NNC(C)C)cc1;
	InChI InChI=1S/C11H15ClN2O2/c1-8(2)13-14-11(15)7-16-10-5-3-9(12)4-6-10/h3-6,8,13H,7H2,1-2H3,(H,14,15) ; Key:GGECDTUJZOXAAR-UHFFFAOYSA-N ;
	(verify)

Iproclozide (trade names Sursum, Sinderesin) is an irreversible and selective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class that was used as an antidepressant, but has since been discontinued.^[2] It has been known to cause fulminant hepatitis and there have been at least three reported fatalities due to administration of the drug.^[3]^[4]

References

^ Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
^ Suerinck A, Suerinck E (April 1966). "[Depressive states in a sanatorium milieu and monoamine oxidase inhibitors. (Therapeutic results by the combination of iproclozide and chlordiazepoxide). Apropos of 146 cases]". Journal de Médecine de Lyon. 47 (96): 573–586. PMID 5930723.
^ Pessayre D, de Saint-Louvent P, Degott C, Bernuau J, Rueff B, Benhamou JP (September 1978). "Iproclozide fulminant hepatitis. Possible role of enzyme induction". Gastroenterology. 75 (3): 492–496. doi:10.1016/0016-5085(78)90856-9. PMID 680506.
^ Kaplowitz N, DeLeve LD (2003). Drug-induced liver disease. Informa Health Care. p. 455. ISBN 0-8247-0811-3.